JP2017514481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514481A5 JP2017514481A5 JP2016565162A JP2016565162A JP2017514481A5 JP 2017514481 A5 JP2017514481 A5 JP 2017514481A5 JP 2016565162 A JP2016565162 A JP 2016565162A JP 2016565162 A JP2016565162 A JP 2016565162A JP 2017514481 A5 JP2017514481 A5 JP 2017514481A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- reagent
- ligand
- receptor molecule
- target cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims description 272
- 239000003153 chemical reaction reagent Substances 0.000 claims description 197
- 239000003446 ligand Substances 0.000 claims description 139
- 210000004027 cell Anatomy 0.000 claims description 118
- 238000000034 method Methods 0.000 claims description 101
- 230000009149 molecular binding Effects 0.000 claims description 94
- 239000007790 solid phase Substances 0.000 claims description 62
- 108010090804 Streptavidin Proteins 0.000 claims description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 230000005526 G1 to G0 transition Effects 0.000 claims description 30
- 150000001413 amino acids Chemical group 0.000 claims description 28
- 230000002441 reversible effect Effects 0.000 claims description 28
- 108090001008 Avidin Proteins 0.000 claims description 25
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 150000001615 biotins Chemical class 0.000 claims description 15
- 238000010494 dissociation reaction Methods 0.000 claims description 15
- 230000005593 dissociations Effects 0.000 claims description 15
- 108010018381 streptavidin-binding peptide Proteins 0.000 claims description 15
- 229960002685 biotin Drugs 0.000 claims description 12
- 235000020958 biotin Nutrition 0.000 claims description 12
- 239000011616 biotin Substances 0.000 claims description 12
- 230000002860 competitive effect Effects 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 229940024606 amino acid Drugs 0.000 claims description 10
- 230000003100 immobilizing effect Effects 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 150000001768 cations Chemical class 0.000 claims description 9
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 8
- 239000011324 bead Substances 0.000 claims description 7
- 102000000584 Calmodulin Human genes 0.000 claims description 6
- 108010041952 Calmodulin Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 230000009920 chelation Effects 0.000 claims description 6
- 102000005720 Glutathione transferase Human genes 0.000 claims description 5
- 108010070675 Glutathione transferase Proteins 0.000 claims description 5
- 229910001428 transition metal ion Inorganic materials 0.000 claims description 5
- 229920002101 Chitin Polymers 0.000 claims description 4
- 108010020195 FLAG peptide Proteins 0.000 claims description 4
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 102000021178 chitin binding proteins Human genes 0.000 claims description 4
- 108091011157 chitin binding proteins Proteins 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 102000002933 Thioredoxin Human genes 0.000 claims description 2
- 101710120037 Toxin CcdB Proteins 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims description 2
- 239000012504 chromatography matrix Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 238000002523 gelfiltration Methods 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 102000028557 immunoglobulin binding proteins Human genes 0.000 claims description 2
- 108091009323 immunoglobulin binding proteins Proteins 0.000 claims description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 108060008226 thioredoxin Proteins 0.000 claims description 2
- 229940094937 thioredoxin Drugs 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims description 2
- 150000003624 transition metals Chemical class 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims 1
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 3
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166718 | 2014-04-30 | ||
| EP14166718.8 | 2014-04-30 | ||
| PCT/EP2015/059510 WO2015166049A1 (en) | 2014-04-30 | 2015-04-30 | Method of isolating a target cell |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514481A JP2017514481A (ja) | 2017-06-08 |
| JP2017514481A5 true JP2017514481A5 (enExample) | 2018-06-14 |
| JP6678593B2 JP6678593B2 (ja) | 2020-04-08 |
Family
ID=50693456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565162A Active JP6678593B2 (ja) | 2014-04-30 | 2015-04-30 | 標的細胞を単離する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11150239B2 (enExample) |
| EP (1) | EP3137905B1 (enExample) |
| JP (1) | JP6678593B2 (enExample) |
| CN (1) | CN106662584B (enExample) |
| AU (1) | AU2015254588B2 (enExample) |
| CA (1) | CA2945414C (enExample) |
| WO (1) | WO2015166049A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606970UA (en) | 2012-02-23 | 2016-10-28 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| KR102714469B1 (ko) * | 2014-04-16 | 2024-10-11 | 주노 테라퓨틱스 게엠베하 | 세포 집단의 증대를 위한 방법, 키트 및 장치 |
| RU2761555C2 (ru) | 2015-10-22 | 2021-12-09 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| ES3038614T3 (en) | 2017-04-27 | 2025-10-14 | Juno Therapeutics Inc | Oligomeric particle reagents and methods of use thereof |
| KR102088277B1 (ko) * | 2018-04-27 | 2020-03-13 | 주식회사 유니언스진 | 면역 화학 진단법을 이용한 표적 항원 검출용 종이기반 3차원 구조의 미세칩과 이를 이용한 표적항원 검출 방법 |
| US20210206857A1 (en) * | 2018-05-21 | 2021-07-08 | Bioprocessia Technologies Llc | Multivalent protein complexes |
| WO2020018578A1 (en) * | 2018-07-17 | 2020-01-23 | University Of Washington | Compositions and methods related to aptamer-based reversible cell selection |
| CN112639434A (zh) * | 2018-08-31 | 2021-04-09 | 热动力医疗公司 | 从血液中分离靶细胞的方法 |
| WO2021152178A1 (en) | 2020-01-31 | 2021-08-05 | Cell.Copedia GmbH | Methods of isolating a biological entity |
| WO2023017115A1 (en) | 2021-08-11 | 2023-02-16 | Iba Lifesciences Gmbh | Fractionation of cells based on a marker protein |
| JP2025514271A (ja) | 2022-04-28 | 2025-05-02 | バイオ－リセル リミテッド | 標的細胞を分離する方法 |
| WO2025238197A1 (en) * | 2024-05-16 | 2025-11-20 | Iba Lifesciences Gmbh | Functionalized three-dimensional (3d) polymer scaffold for affinity chromatography |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0198015B2 (en) | 1984-10-02 | 1995-07-19 | Biogen, Inc. | Production of streptavidin-like polypeptides |
| US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| AU708375B2 (en) | 1995-02-09 | 1999-08-05 | University Of Washington | Modified-affinity streptavidin |
| AU5917796A (en) | 1995-04-11 | 1997-04-09 | Trustees Of Boston University | Streptavidin mutants |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| AU6701498A (en) | 1997-03-14 | 1998-09-29 | Trustees Of Boston University | Multiflavor streptavidin |
| US5985658A (en) | 1997-11-14 | 1999-11-16 | Health Research Incorporated | Calmodulin-based cell separation technique |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2006115129A1 (ja) | 2005-04-19 | 2006-11-02 | Matsushita Electric Industrial Co., Ltd. | 位置センサ、光ヘッド装置、ヘッド移動機構、情報記録再生装置、および位置制御システム |
| AU2007353319A1 (en) * | 2006-11-15 | 2008-11-20 | Invitrogen Dynal As | Methods for reversibly binding a biotin compound to a support |
| US8008032B2 (en) * | 2008-02-25 | 2011-08-30 | Cellective Dx Corporation | Tagged ligands for enrichment of rare analytes from a mixed sample |
| WO2012044999A2 (en) * | 2010-10-01 | 2012-04-05 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
| TR201811128T4 (tr) * | 2011-07-18 | 2018-08-27 | Iba Gmbh | Bir hedef hücrenin tersinir şekilde boyama yöntemi. |
| SG10201606970UA (en) | 2012-02-23 | 2016-10-28 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
-
2015
- 2015-04-30 EP EP15723655.5A patent/EP3137905B1/en active Active
- 2015-04-30 CA CA2945414A patent/CA2945414C/en active Active
- 2015-04-30 JP JP2016565162A patent/JP6678593B2/ja active Active
- 2015-04-30 CN CN201580035819.4A patent/CN106662584B/zh active Active
- 2015-04-30 AU AU2015254588A patent/AU2015254588B2/en active Active
- 2015-04-30 US US15/306,995 patent/US11150239B2/en active Active
- 2015-04-30 WO PCT/EP2015/059510 patent/WO2015166049A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514481A5 (enExample) | ||
| JP6475630B2 (ja) | ストレプトアビジン突然変異タンパク質およびそれらを使用する方法 | |
| RU2016144724A (ru) | Способы, наборы и устройство для размножения популяции клеток | |
| JP2017513524A5 (enExample) | ||
| CN102892885B (zh) | IgA结合性肽以及利用其的IgA的纯化 | |
| TW200940989A (en) | A method for characterization of a recombinant polyclonal protein | |
| CN106662584A (zh) | 分离靶细胞的方法 | |
| Mukherjee et al. | A new versatile immobilization tag based on the ultra high affinity and reversibility of the calmodulin–calmodulin binding peptide interaction | |
| JP2023506961A (ja) | ナノボディー交換クロマトグラフィー | |
| RU2018138782A (ru) | Антитела к фактору ix padua | |
| JP5042237B2 (ja) | 血小板抗原特異抗体の結合を中和するペプチドアプタマー並びにそれを含む診断及び治療への応用 | |
| CN104597256A (zh) | 一条与牛病毒性腹泻病毒e2蛋白相结合的多肽序列及其应用 | |
| Geumann et al. | A sandwich enzyme-linked immunosorbent assay for the quantification of insoluble membrane and scaffold proteins | |
| JP2023541807A (ja) | Ｍｈｃｉペプチド結合の特徴づけのためのアッセイおよび試薬 | |
| WO2013081037A1 (ja) | IgA結合性ペプチド及びそれによるIgAの精製 | |
| CN106990252A (zh) | 用于诊断活动性结核的方法和试剂盒 | |
| JP2017512200A5 (enExample) | ||
| US11796545B2 (en) | Methods and kits for determining binding sites | |
| JP2017533913A5 (enExample) | ||
| JP6245688B2 (ja) | ＩｇＹ特異的結合ペプチド及びそれによるＩｇＹの精製法 | |
| Säll et al. | Advancing the global proteome survey platform by using an oriented single chain antibody fragment immobilization approach | |
| WO2011068538A2 (en) | General method for generating ultra-high affinity binding proteins | |
| JPWO2023277122A5 (enExample) | ||
| CN105486855B (zh) | 改良间接酶联免疫吸附法 | |
| CN105348378B (zh) | 副肿瘤性天疱疮的抗原evpl-l3及其应用 |